Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes

Arthritis and Rheumatism

Volumn 52, Issue 10, 2005, Pages 3063-3072

  Li, Jianwei ^a   Liu, Yang ^a   Xie, Chun ^a   Zhu, Jiankun ^a   Kreska, Desi ^a   Morel, Laurence ^b   Mohan, Chandra ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONGENIC STRAIN; CONTROLLED STUDY; DNA POLYMORPHISM; GENE; GENE EXPRESSION; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; IFN I GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SLE2 GENE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; INTERFERON-ALPHA; INTERFERON-BETA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, CONGENIC; MICE, INBRED C57BL; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 26844573357     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21307     Document Type: Article

References (66)

1. Pascual V, Banchereau J, Palucka AK. The central role of dendritic cells and interferon-α in SLE. Curr Opin Rheumatol 2003;15:548-56.
2. Jorgensen TN, Gubbels MR, Kotzin BL. Links between type I interferons and the genetic basis of disease in mouse lupus. Autoimmunity 2003;36:491-502.
3. Crow MK, Kirou KA. Interferon-α in systemic lupus erythematosus. Curr Opin Rheumatol 2004;16:541-7.
4. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose Interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
5. Ronnblom LE, Aim GV, Oberg KE. Autoimmunity after α-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-83.
6. Tolaymat A, Leventhal B, Sakarcan A, Kashima H, Monteiro C. Systemic lupus erythematosus in a child receiving long-term Interferon therapy. J Pediatr 1992;120:429-32.
7. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after Interferon therapy for chronic myelogenous leukemia. Cancer 1991;68: 1536-7.
8. Flores A, Olive A, Feliu E, Tena X. Systemic lupus erythematosus following interferon therapy. Br J Rheumatol 1994;33:787.
9. Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving α-interferon therapy. Cancer 1990;65:2237-42.
10. Wandl UB, Nagel Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992;65:70-4.
11. Ehrenstein MR, McSweeney E, Swana M, Worman CP, Goldstone AH, Isenberg DA. Appearance of anti-DNA antibodies in patients treated with interferon-α. Arthritis Rheum 1993;36:279-80.
12. Kalkner KM, Ronnblom L, Karlsson PA, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998;91:393-9.
13. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25: 401-6.
14. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003;36:481-90.
15. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
16. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-5.
17. Dandoy F, Kelley KA, DeMaeyer-Guignard J, DeMaeyer E, Pitha PM. Linkage analysis of the murine interferon-α locus on chromosome 4. J Exp Med 1984;160:294-302.
18. Mohan C. Murine lupus genetics: lessons learned. Curr Opin Rheumatol 2001;13:352-60.
19. Knight JG, Adams DD. Genes determining autoimmune disease in New Zealand mice. J Clin Lab Immunol 1981;5:165-70.
20. Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994;1:219-29.
21. Kono DH, Burlingame RW, Owens DG, Kuramochi A, Balderas RS, Balomenos D, et al. Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci U S A 1994;91:10168-72.
22. Rozzo SJ, Vyse TJ, Drake CG, Kotzin BL. Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis. Proc Natl Acad Sci U S A 1996;93: 15164-8.
23. Ida A, Hirose S, Hamano Y, Kodera S, Jiang Y, Abe M, et al. Multigenic control of lupus-associated antiphospholipid syndrome in a model of (NZW × BXSB) F1 mice. Eur J Immunol 1998;28: 2694-703.
24. Hogarth MB, Slingsby JH, Allen PJ, Thompson EM, Chandler P, Davies KA, et al. Multiple lupus susceptibility loci map to chromosome 1 in BXSB mice. J Immunol 1998;161:2753-61.
25. Tucker RM, Vyse TJ, Rozzo S, Roark CL, Izui S, Kotzin BL. Genetic control of glycoprotein 70 autoantigen production and its influence on immune complex levels and nephritis in murine lupus. J Immunol 2000;165:1665-72.
26. Xu Z, Butfiloski EJ, Sobel ES, Morel L. Mechanisms of peritoneal B-1a cells accumulation induced by murine lupus susceptibility locus Sle2. J Immunol 2004;173:6050-8.
27. Morel L, Mohan C, Yu Y, Croker B, Tian XH, Deng A, et al. Functional dissection of SLE pathogenesis using congenic mouse strains. J Immunol 1997;158:6019-28.
28. Mohan C, Morel L, Croker B, Yang P, Wakeland EK. Genetic dissection of SLE pathogenesis: Sle2 on murine chromosome 4 leads to B-cell hyperactivity. J Immunol 1997;159:454-65.
29. Mohan C, Morel L, Yang P, Wakeland EK. Accumulation of splenic B1a cells with potent antigen-presenting capability in NZM2410 lupus-prone mice. Arthritis Rheum 1998;41:1652-62.
30. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918-21.
31. Mohan C, Morel L, Yang P, Watanabe H, Croker B, Gilkeson G, et al. Genetic dissection of SLE pathogenesis: a recipe for nephrophilic autoantibodies. J Clin Invest 1999;103:1685-95.
32. Shi X, Xie C, Kreska D, Richardson J, Mohan C. Genetic dissection of SLE: Sle1 and Fas impact distinct pathways leading to lymphoproliferative autoimmunity. J Exp Med 2002;196:281-92.
33. Kelley KA, Pitha PM. Characterization of a mouse interferon gene locus. I. Isolation of a cluster of four α interferon genes. Nucleic Acids Res 1985;13:805-23.
34. Kelley KA, Pitha PM. Characterization of a mouse interferon gene locus. II. Differential expression of α-interferon genes. Nucleic Acids Res 1985;13:825-39.
35. Zwarthoff EC, Mooren AT, Trapman J. Organization, structure and expression of murine interferon α genes. Nucleic Acids Res 1985;13:791-804.
36. Dion M, Vodjdani G, Doly J. Sequence and expression of a novel murine interferon α gene: homology with enhancer elements in the regulatory region of the gene. Biochem Biophys Res Commun 1986;138:826-34.
37. Coulombel C, Vodjdani G, Doly J. Isolation and characterization of a novel interferon-a-encoding gene, IFN-α 11, within a murine IFN cluster. Gene 1991;104:187-95.
38. Hughes TK, Chin R, Tyring SK, Rady PL. Distinction of mouse interferon-α subtypes by polymerase chain reaction utilizing consensus primers and type-specific oligonucleotide probes. J Interferon Res 1994;14:117-20.
39. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197: 777-88.
40. Braun D, Geraldes P, Demengeot J. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003;20:15-25.
41. Wang J, Lin Q, Langsten H, Cooper MD. Resident bone marrow macrophages produce type 1 interferons that can selectively inhibit interleukin-7-driven growth of B lineage cells. Immunity 1995;3: 475-84.
42. Demengeot J, Vasconcellos R, Modigliani Y, Grandien A, Coutinho A. B lymphocyte sensitivity to IgM receptor ligation is independent of maturation stage and locally determined by macrophage-derived IFNβ. Int Immunol 1997;9:1677-85.
43. Vasconcellos R, Braun D, Coutinho A, Demengeot J. Type I IFN sets the stringency of B-cell repertoire selection in the bone marrow. Int Immunol 1999;11:279-88.
44. Liang Z, Xie C, Chen C, Kreska D, Hsu K, Li L, et al. Pathogenic profiles and molecular signatures of ANAs derived from NZM2410 lupus mice. J Exp Med 2004;199:381-98.
45. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995;3:39-50.
46. Crow MK. Interferon-α: a new target for therapy in systemic lupus erythematosus? [editorial]. Arthritis Rheum 2003;48:2396-401.
47. Stewart TA. Neutralizing interferon α as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev 2003;14: 139-54.
48. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004;173:2134-42.
49. Chaouchi N, Wallon C, Taieb J, Auffredou MT, Tertian G, Lemoine FM, et al. Interferon-α-mediated prevention of in vitro apoptosis of chronic lymphocytic leukemia B-cells: role of bcl-2 and c-myc. Clin Immunol Immunopathol 1994;73:197-204.
50. Brass U, Tretter T, Schneller F, Schuler M, Huber C, Peschel C. IFN-α stimulates proliferation and cytokine secretion of CD40-stimulated B cell chronic lymphocytic leukemia cells in vitro. J Interferon Cytokine Res 1999;19:335-43.
51. Hibbert L, Foster GR. Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J Interferon Cytokine Res 1999;19:309-18.
52. Morikawa K, Kubagawa H, Suzuki T, Cooper MD. Recombinant interferon-α, -β, and -γ enhance the proliferative response of human B cells. J Immunol 1987;139:761-6.
53. Saily M, Koistinen P, Laine S, Soppi E, Savolainen ER. Effect of interferon-α on immunoglobulin production by peripheral blood mononuclear cells in multiple myeloma. Eur J Haematol 1996;57: 171-7.
54. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999;189:521-30.
55. Chakrabarti D, Hultgren B, Stewart TA. IFN-α induces auto-immune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 1996;157:522-8.
56. Aman MJ, Tretter T, Eisenbeis I, Bug G, Decker T, Aulitzky WE, et al. Interferon-α stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood 1996;87:4731-6.
57. Bug G, Aman MJ, Tretter T, Huber C, Peschel C. Induction of macrophage-inflammatory protein Ia (MIP-1α) by interferon-α. Exp Hematol 1998;26:117-23.
58. Kolosov M, Kolosova I, Zhou A, Leu RW. Autocrine induction of macrophage synthesis of complement subcomponent C1q by endogenous interferon-α/ β. J Interferon Cytokine Res 1996;16: 209-15.
59. Lopez-Collazo E, Hortelano S, Bosca L. Interferon-α/β inhibits the apoptosis induced by lipopolysaccharide and interferon-γ ; in murine peritoneal macrophages. J Interferon Cytokine Res 1998; 18:461-7.
60. Lian ZX, Kikuchi K, Yang GX, Ansari AA, Ikehara S, Gershwin ME. Expansion of bone marrow IFN-α-producing dendritic cells in New Zealand black (NZB) mice: high level expression of TLR9 and secretion of IFN-α in NZB bone marrow. J Immunol 2004; 173:5283-9.
61. Vassileva G, Chen SC, Zeng M, Abbondanzo S, Jensen K, Gorman D, et al. Expression of a novel murine type I IFN in the pancreatic islets induces diabetes in mice. J Immunol 2003;170: 5748-55.
62. Gysemans C, van Etten E, Overbergh L, Verstuyf A, Waer M, Bouillon R, et al. Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-β in combination with an analogue of 1a,25- dihydroxyvitamin-D3. Clin Exp Immunol 2002;128:213-20.
63. Akwa Y, Hassett DE, Eloranta ML, Sandberg K, Masliah E, Powell H, et al. Transgenic expression of IFN-α in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol 1998;161:5016-26.
64. Billiau A, Kieseier BC, Hartung HP. Biologic role of Interferon β in multiple sclerosis. J Neurol 2004;251 Suppl 2:1110-4.
65. Bayas A, Gold R. Lessons from 10 years of interferon β-1b (Betaferon/Betaseron) treatment. J Neurol 2003;250 Suppl 4: IV3-8.
66. Brod SA. Autoimmunity is a type I interferon-deficiency syndrome corrected by ingested type I IFN via the GALT system. J Interferon Cytokine Res 1999;19:841-52.